citalopram has been researched along with Movement Disorders in 6 studies
Citalopram: A furancarbonitrile that is one of the serotonin uptake inhibitors used as an antidepressant. The drug is also effective in reducing ethanol uptake in alcoholics and is used in depressed patients who also suffer from TARDIVE DYSKINESIA in preference to tricyclic antidepressants, which aggravate dyskinesia.
citalopram : A racemate comprising equimolar amounts of (R)-citalopram and its enantiomer, escitalopram. It is used as an antidepressant, although only escitalopram is active.
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile : A nitrile that is 1,3-dihydro-2-benzofuran-5-carbonitrile in which one of the hydrogens at position 1 is replaced by a p-fluorophenyl group, while the other is replaced by a 3-(dimethylamino)propyl group.
Movement Disorders: Syndromes which feature DYSKINESIAS as a cardinal manifestation of the disease process. Included in this category are degenerative, hereditary, post-infectious, medication-induced, post-inflammatory, and post-traumatic conditions.
| Excerpt | Relevance | Reference |
|---|---|---|
| " A selective serotonergic drug (citalopram) or a placebo was administered using a mean dosage of 10 mg/day in combination with physiotherapy." | 2.74 | A double blind placebo RCT to investigate the effects of serotonergic modulation on brain excitability and motor recovery in stroke patients. ( Acler, M; Fiaschi, A; Manganotti, P; Robol, E, 2009) |
| "Citalopram-induced LA was dose-dependently attenuated by the 5-HT1B/1D receptor antagonists, S18127, GR125,743 and GR127,935, and by the selective 5-HT1B antagonist, SB224,289, but unaffected by the selective 5-HT1A antagonist, WAY100,635." | 1.32 | Blockade of serotonin 5-HT1B and 5-HT2A receptors suppresses the induction of locomotor activity by 5-HT reuptake inhibitors, citalopram and fluvoxamine, in NMRI mice exposed to a novel environment: a comparison to other 5-HT receptor subtypes. ( Brocco, M; Girardon, S; Millan, MJ; Veiga, S, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nowidi, K | 1 |
| Kunisch, R | 1 |
| Bouna-Pyrrou, P | 1 |
| Meißner, D | 1 |
| Hennig-Fast, K | 1 |
| Weindl, A | 1 |
| Förster, S | 1 |
| Neuhann, TM | 1 |
| Falkai, P | 1 |
| Berger, M | 1 |
| Musil, R | 1 |
| Acler, M | 1 |
| Robol, E | 1 |
| Fiaschi, A | 1 |
| Manganotti, P | 1 |
| Rozzini, L | 1 |
| Chilovi, BV | 1 |
| Conti, M | 1 |
| Bertoletti, E | 1 |
| Zanetti, M | 1 |
| Trabucchi, M | 1 |
| Padovani, A | 1 |
| Birthi, P | 1 |
| Walters, C | 1 |
| Karandikar, N | 1 |
| Algahtani, HA | 1 |
| Seddeq, YA | 1 |
| Alfudhail, AM | 1 |
| Abdu, A | 1 |
| Millan, MJ | 1 |
| Veiga, S | 1 |
| Girardon, S | 1 |
| Brocco, M | 1 |
1 trial available for citalopram and Movement Disorders
| Article | Year |
|---|---|
A double blind placebo RCT to investigate the effects of serotonergic modulation on brain excitability and motor recovery in stroke patients.
Topics: Administration, Oral; Aged; Brain; Citalopram; Dominance, Cerebral; Double-Blind Method; Evoked Pote | 2009 |
5 other studies available for citalopram and Movement Disorders
| Article | Year |
|---|---|
[The White man's burden - a case study caught between bipolar affective disorder and Huntington's disease].
Topics: Antidepressive Agents; Antipsychotic Agents; Bipolar Disorder; Citalopram; Dibenzothiazepines; Femal | 2013 |
Efficacy of SSRIs on cognition of Alzheimer's disease patients treated with cholinesterase inhibitors.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Citalopram; Cognition; Cognition Disorders; Depr | 2010 |
A rare case of tardive dyskinesia and akathisia induced by citalopram.
Topics: Adult; Akathisia, Drug-Induced; Citalopram; Humans; Male; Movement Disorders; Selective Serotonin Re | 2010 |
A young women who couldn't see or move.
Topics: Adolescent; Basal Ganglia; Cerebral Cortex; Citalopram; Coma; Female; Hemoglobins; Humans; Magnetic | 2011 |
Blockade of serotonin 5-HT1B and 5-HT2A receptors suppresses the induction of locomotor activity by 5-HT reuptake inhibitors, citalopram and fluvoxamine, in NMRI mice exposed to a novel environment: a comparison to other 5-HT receptor subtypes.
Topics: Animals; Citalopram; Environment Design; Fluvoxamine; Injections, Subcutaneous; Male; Mice; Motor Ac | 2003 |